D-Glucarate · CDG
Calcium D-Glucarate (CDG) is the calcium salt of D-glucaric acid, a naturally occurring molecule found in small amounts in fruits and vegetables (apples, grapefruit, cruciferous vegetables, sprouts). After oral ingestion, CDG releases D-glucaric acid which is converted to D-glucaro-1,4-lactone - the biologically active form responsible for its effects.
Can be taken with or without food. Split dosing (3x daily) maintains steady beta-glucuronidase inhibition. Often paired with DIM for comprehensive estrogen management. Take separate from medications that should not have enhanced clearance.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
After oral ingestion, CDG releases D-glucaric acid which is metabolized to D-glucaro-1,4-lactone (GL). GL is the biologically active inhibitor of beta-glucuronidase enzyme.
Beta-glucuronidase is produced primarily by gut bacteria (E. coli, Clostridium, Bacteroides) and to a lesser extent by host tissues. Elevated beta-glucuronidase activity is common in dysbiosis, constipation, high-meat diets, and certain disease states.
When the liver detoxifies estrogens and other compounds, it conjugates them with glucuronic acid (Phase II glucuronidation), making them water-soluble for biliary excretion. These conjugates pass into the gut for elimination. If beta-glucuronidase activity is high, the glucuronide bond is cleaved in the gut, releasing free (unconjugated) estrogen/toxin which can be reabsorbed across the intestinal wall back into circulation - the 'enterohepatic recirculation' pathway.
By inhibiting beta-glucuronidase, CDG/GL keeps conjugated estrogens and toxins LOCKED in their glucuronide form, ensuring they pass through the gut and are eliminated in stool rather than reabsorbed. This effectively increases the elimination of estrogens, xenobiotics, and bile acids.
CDG also induces hepatic Phase II UGT (UDP-glucuronosyltransferase) enzymes, increasing the rate at which the liver conjugates compounds for excretion - working synergistically with the beta-glucuronidase inhibition.
Cancer chemoprevention: animal models of mammary, colon, and skin carcinogenesis show CDG reduces tumor formation, attributed to enhanced clearance of carcinogens and pro-carcinogens before they damage DNA.
Weeks 1-2: Initial gut and excretion changes.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Mechanism boundary: oral calcium-D-glucarate supplementation has been reported to inhibit beta-glucuronidase.
Oral supplementation of calcium-D-glucarate has been shown to inhibit beta-glucuronidase, an enzyme produced by colonic microflora and involved in Phase II liver detoxification.
Evidence scope. Narrative monograph/review; exact oral molecule and mechanism are stated, but no population, dose, clinical endpoint, or safety dataset is given in the abstract.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500 mg orally 1-3 times daily. No checked human abstract administered calcium-D-glucarate at this dose and frequency.
Primary safety: tolerability and medication/contraceptive-clearance concerns at the displayed regimen. No checked human abstract established safety or the page’s drug-clearance and contraceptive claims at 500 mg 1-3 times daily.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
D-glucaro-1,4-lactone (active form): ~6-8 hours plasma.
Oral.
Plasma clearance 12-24 hours. Beta-glucuronidase inhibition effects align with plasma curve.
Modest - CDG is hydrolyzed in stomach to D-glucaric acid which is then absorbed and converted to active GL. Estimates ~30-50% bioavailability.
Acute beta-glucuronidase inhibition: 6-12 hours per dose (hence 2-3x daily dosing). Chronic estrogen clearance effects build over 4-8 weeks.
Hepatic and intestinal metabolism. Metabolites excreted in urine and bile.
Storage. Store at room temperature (20-25C) in a cool, dry place. Protect from moisture. Capsules and tablets shelf-stable 2+ years.
Classified as a dietary supplement in the US - no prescription required. Widely available. No FDA-approved medical indication.
Put it to work
Open Calcium D-Glucarate straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Calcium D-Glucarate in the app →Go deeper
The complete Calcium D-Glucarate walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.